tirzepatide lilly direct cost markets single-dose Zepbound vials at a major price cut FDA approves tirzepatide, Eli Lilly's

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020

Emerging GLP-1 options and future coverage possibilities The GLP-1 landscape is evolving rapidly, and emerging alternatives may offer new insurance coverage opportunities

In the PIONEER 4 trial, 711 patients with diabetes were randomised to oral semaglutide 14mg, liraglutide 1.mg and placebo

EMBO J,1992;11(7): 2373-79

Subjective feelings alone are insufficientuse quantifiable metrics to guide protocol adjustments

If necessary, consult with your healthcare provider to adjust your treatment plan and ensure youre getting the most out of your therapy